Dianthus Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 13.75 million compared to USD 7.09 million a year ago.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
21.77 USD | -5.55% | -17.07% | +109.33% |
05-16 | HC Wainwright Initiates Dianthus Therapeutics With Buy Rating, $40 Price Target | MT |
05-10 | Wedbush Adjusts Dianthus Therapeutics' Price Target to $38 From $33, Keeps Outperform Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+109.33% | 639M | |
+10.79% | 116B | |
+11.65% | 106B | |
-6.20% | 23.89B | |
-3.41% | 21.58B | |
-10.58% | 18.96B | |
-13.41% | 16.33B | |
-40.50% | 16.96B | |
+6.64% | 14.14B | |
+31.84% | 12.02B |
- Stock Market
- Equities
- DNTH Stock
- News Dianthus Therapeutics, Inc.
- Dianthus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024